Oragenics Inc. (NYSE American: OGEN), a clinical-stage biotechnology company focused on brain-targeted therapeutics, announced that all three sites in its Australian Phase IIa clinical trial of ONP-002 for mild traumatic brain injury (concussion) are now active and enrolling participants. The activation of Royal Adelaide Hospital completes the site initiation process, enabling full enrollment across the trial.
The company reported that no serious adverse events have been observed in participants dosed to date. Oragenics continues to target a Phase IIa data readout in the fourth quarter of 2026. ONP-002 is being developed as a potential first-in-class treatment for concussion and mild traumatic brain injury, delivered via the company's proprietary intranasal delivery technology.
In parallel with the Australian trial, Oragenics submitted a Type B meeting request to the U.S. Food and Drug Administration on June 26 to obtain guidance on its planned U.S. clinical development program for ONP-002. The company stated that the meeting supports its goal of submitting an Investigational New Drug application in the fourth quarter of 2026.
The intranasal delivery platform used for ONP-002 has potential applications across multiple neurological conditions, including Parkinson's disease, Alzheimer's disease, PTSD, and anxiety disorders. Oragenics is committed to developing innovative therapies that address significant unmet medical needs in neurological care.
The advancement of ONP-002 is significant given the lack of approved pharmacologic treatments for concussion and mild traumatic brain injury, which affect millions of people worldwide. If successful, ONP-002 could become a first-in-class therapy, offering a new option for patients and potentially reducing the long-term consequences of repetitive head injuries.
Investors and stakeholders can find the latest news and updates regarding OGEN in the company's newsroom at https://ibn.fm/OGEN. For more information about Oragenics, visit oragenics.com.
